f acute cardiovascular and neurological conditions in the Chinese market estimated to be worth more than 2 billion RMB annually at peak sales." Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said: "This is a breakthrough for our business development as it is the first time Sihuan Pharmaceutical